ERZOFRI EXTENDED-RELEASE: payments to doctors
Payments that named ERZOFRI EXTENDED-RELEASE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $301K
- Providers
- 1,868
- Transactions
- 3,208
- Average per transaction
- $94
The per-transaction average — $94 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,868 providers the average total is $161, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Luye Pharma (USA) Ltd. | $300,711 | 100.0% |